Back to Search Start Over

Enhancing the Response Rate to Recombinant Uricases in Patients with Gout.

Authors :
Schlesinger N
Padnick-Silver L
LaMoreaux B
Source :
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2022 Mar; Vol. 36 (2), pp. 95-103. Date of Electronic Publication: 2022 Mar 22.
Publication Year :
2022

Abstract

Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower serum uric acid below the therapeutic threshold with oral urate-lowering therapies such as allopurinol and febuxostat. Recombinant uricase is increasingly being used to treat refractory gout; however, the immunogenicity of uricase-based therapies has limited the use of these biologic therapies. Antidrug antibodies against biologic therapies, including uricase and PEGylated uricase, can lead to loss of urate-lowering response, increased risk of infusion reactions, and subsequent treatment failure. However, co-therapy with an immunomodulator can attenuate antidrug antibody development, potentially increasing the likelihood of sustained urate lowering, therapy course completion, and successful treatment outcomes. This review summarizes evidence surrounding the use of immunomodulation as co-therapy with recombinant uricases.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1179-190X
Volume :
36
Issue :
2
Database :
MEDLINE
Journal :
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Publication Type :
Academic Journal
Accession number :
35316517
Full Text :
https://doi.org/10.1007/s40259-022-00517-x